AstraZeneca Shares Sink on Lackluster Mystic Drug Results

AstraZeneca (AZN) - Get Report posted lackluster trial results for a pipeline lung cancer drug - Mystic.

The drug didn't prove more effective than standard chemotherapy.

This was the very drug that helped AstraZeneca defend itself against Pfizer's $91 billion bid for the company three years ago.

AstraZeneca shares are down over 15%.